Upstream Bio CMO has 895 shares sold for taxes
Upstream Bio, Inc. reported that Chief Medical Officer Aaron Deykin sold 895 shares of common stock at $6.10 per share on June 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Upstream Bio, Inc. reported that Chief Medical Officer Aaron Deykin sold 895 shares of common stock at $6.10 per share on June 16, 2026. According to the company’s sell-to-cover policy, these shares were sold automatically to cover tax withholding on vested restricted stock units and were not sold at his discretion.
After this transaction, Deykin directly holds 33,197 shares of Upstream Bio common stock, which includes 1,405 shares previously acquired under the company’s 2024 Employee Stock Purchase Plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 895 | $6.10 | $5K |
Footnotes (2)
- F1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- F2. Includes 1,405 shares of Common Stock previously acquired under the Issuer's 2024 Employee Stock Purchase Plan.
Key Figures
Key Terms
sell-to-cover financial
restricted stock units financial
Employee Stock Purchase Plan financial
open-market sale financial
AI-generated analysis. How Rhea-AI works. Not financial advice.